A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT ID: NCT03661866
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
15000 participants
OBSERVATIONAL
2018-12-21
2050-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Drug Survival of Target Therapies in Atopic Dermatitis
NCT06882148
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
NCT05984784
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901
Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
NCT05098821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Participant has plans for future visits at the site for continued management of IMISC.
Exclusion Criteria
* 2\. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Target PharmaSolutions, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura Dalfonso
Role: STUDY_DIRECTOR
Target RWE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clear Dermatology & Aesthetics Center/Investigative MD
Scottsdale, Arizona, United States
Johnson Dermatology
Fort Smith, Arkansas, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Arkansas Dermatology
Little Rock, Arkansas, United States
First OC Dermatology
Fountain Valley, California, United States
Center for Dermatology Cosmetic and Laser Surgery
Fremont, California, United States
University of California
Irvine, California, United States
University of California - San Diego/Rady Children's Hospital
San Diego, California, United States
George Washington University
Washington D.C., District of Columbia, United States
Feinstein Dermatology and Cosmetic Surgery
Hollywood, Florida, United States
Academic Alliance in Dermatology
Tampa, Florida, United States
Integrated Dermatology of West Palm Beach
West Palm Beach, Florida, United States
Lurie Children's Hospital/Northwestern University
Chicago, Illinois, United States
Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group
Indianapolis, Indiana, United States
The University of Kansas Medical Center
Kansas City, Kansas, United States
Family Allergy and Asthma Research Institute
Louisville, Kentucky, United States
DermAssociates, LCC
Rockville, Maryland, United States
Integrated Dermatology of Massachusetts
Quincy, Massachusetts, United States
University of Massachusetts Medical School
Worcester, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Carl Thornblade, MD, PLLC
Missoula, Montana, United States
South Lincoln Dermatology Clinic
Lincoln, Nebraska, United States
Advanced Dermatology of the Midlands
Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Windsor Dermatology
East Windsor, New Jersey, United States
Linda Susan Marcus
Wyckoff, New Jersey, United States
Centurion Dermatology
Brooklyn, New York, United States
The University of Buffalo
Buffalo, New York, United States
Empire Dermatology
East Syracuse, New York, United States
Forest Hills Dermatology Group
Forest Hills, New York, United States
Greenwich Village Dermatology
New York, New York, United States
Ichan School of Medicine
New York, New York, United States
Advanced Allergy & Asthma, PLLC
Rockville Centre, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Allergy Partners of Western North Carolina
Asheville, North Carolina, United States
UNC Dermatology
Chapel Hill, North Carolina, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
Allergy, Asthma & Clinical Research Center
Oklahoma City, Oklahoma, United States
Oregon Health and Science University
Portland, Oregon, United States
Allergy and Clinical Immunology
Pittsburgh, Pennsylvania, United States
The Medical University of South Carolina
Charleston, South Carolina, United States
El Paso Dermatology Center
El Paso, Texas, United States
North Texas Center for Clinical Research
Frisco, Texas, United States
Asthma and Allergy Center
Lewisville, Texas, United States
Center for Clinical Studies
Webster, Texas, United States
Allergy Associates of Utah
Murray, Utah, United States
University of Utah MidValley Dermatology
Murray, Utah, United States
Virginia Commonwealth University
Richmond, Virginia, United States
North Sound Dermatology
Mill Creek, Washington, United States
Spokane Dermatology Clinic
Spokane, Washington, United States
Dermatology Center for Skin Health
Morgantown, West Virginia, United States
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Skin Centre for Dermatology
Peterborough, Ontario, Canada
York Dermatology Clinic and Research Centre
Richmond Hill, Ontario, Canada
Innovaderm Research, Inc.
Montreal, Quebec, Canada
Saskatoon Dermatology Centre
Saskatoon, Saskatchewan, Canada
Dermatologische Gemeinschaftspraxis Mahlow
Mahlow, Bradenburg, Germany
Dr. Bernhard Korge
Düren, North Rhine-Westphalia, Germany
UKSH- Institut für Entzündungsmedizin
Lübeck, Schleswig-Holstein, Germany
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Universitario La Princesa
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, Krueger J, Harris JE, Dalfonso L, Watkins SE, Crawford JM, Thaci D, Guttman-Yassky E. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open. 2020 Nov 27;10(11):e039928. doi: 10.1136/bmjopen-2020-039928.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TARGET-DERM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.